Important myfortic^® Trials

Enteric coating has been suggested as a potential method of improving the therapeutic window of mycophenolic acid, the intent being to enhance tolerability relative to exposure. For this reason, enteric-coated myfortic was developed. This section provides citations to papers that describe studies evaluating myfortic for safety and efficacy, and establish that patients can be safely converted from mycophenolate mofetil (MMF) to myfortic.

References

1.	Granger DK. Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc. 2001;33:3241-3244.
2.	Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004;4:237-243.
3.	Salvadori M. Therapeutic equivalence of mycophenolate sodium versus mycophenolate mofetil in de novo renal transplant recipients. Transplant Proc. 2001;33:3245-3247.
4.	Salvadori M, Holzer H, De Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4:231-236.

Click here for full prescribing information, which includes contraindications, warnings, precautions, and adverse events.

Back to top